Generic vs brand forms of direct acting antivirals for hepatitis C virus treatment in Egyptian children

Table 3 Treatment adverse events in children receiving generic vs branded direct acting antivirals, n (%)

Adverse event	Patients who received Ledisbuvir (n = 43)	Patients who received Harvoni® (n = 73)	P value
Headache	16 (37.2)	36 (49.3)	0.2
Asthenia/fatigue	16 (37.2)	39 (53.4)	0.1
Irritability	13 (30.2)	29 (39.7)	0.3
Dizziness	7 (16.3)	26 (35.6)	0.03
Cough	14 (32.6)	20 (27.4)	0.7
Nausea	8 (18.6)	13 (17.8)	1.0
Dyspnea	7 (16.3)	13 (17.8)	1.0
Diarrhea	5 (11.6)	13 (17.8)	0.4
Insomnia	5 (11.6)	11 (15.1)	0.8

Pearson χ² or Fisher’s exact test was used for comparing proportions of adverse events.